免疫疗法药物市场规模、份额、成长分析、按类型、按应用、按给药途径、按分销管道、按最终用户、按地区 - 行业预测，2024-2031 年

2022年全球免疫疗法药物市场规模约为2,474.4亿美元，高于2023年的2,853亿美元，预测期间（2024-2031年）复合年增长率为15.3%，到2031年预计将达到772.87美元十亿。

全球免疫疗法药物市场正在经历显着增长，这主要是由慢性病（尤其是糖尿病）患病率上升所推动，根据国际糖尿病联盟的数据，20-79岁成年人的患病率预计到2021年将达到5%，影响3.7亿人。领先的市场参与者越来越注重创新产品开发和策略联盟，以加强免疫疗法研究。 COVID-19 大流行正在推动对免疫疗法相关药物的需求，2021 年 1 月发表的研究结果突显了单株抗体在预防高风险 COVID-19 患者住院方面的功效，并进一步加速了这种增长。免疫治疗产品监管核准的快速增加也支持了市场扩张。关键的成长要素包括与传统治疗相比，人们越来越偏好标靶治疗、生物相似药的引入、文明病的增加以及消费者对单株抗体的需求不断增长。此外，研究合作的激增、研究机构的建立以及生物技术和製药公司的大量研发投资也促进了市场动力。总之，这些动态为未来几年免疫疗法的开发和商业化提供了坚实的前景。

目录

介绍

• 研究目的
• 定义
• 市场范围

调查方法

• 资讯采购
• 二手资料来源和主要资料来源
• 市场规模预测
• 市场假设与限制

执行摘要

• 市场概况展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 波特的分析

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 客户和购买标准分析
• 价值链分析
• 供应链分析
• 价格分析
• 专利分析
• 技术分析
• 案例研究分析
• 监管环境

免疫治疗药物市场：按类型

• 市场概况
• 抗体医药品
• 抑制剂
• 干扰素和白细胞介素
• 癌症疫苗
• 其他类型

免疫治疗市场：依给药途径

• 市场概况
• 静脉注射途径
• 皮下给药途径
• 其他给药途径

免疫治疗药物市场：依应用分类

• 市场概况
• 癌症
• 自体免疫疾病与发炎疾病
• 血
• 骨
• 神经
• 其他用途

免疫治疗药物市场：依分销管道分类

• 市场概况
• 零售药房
• 网路药房
• 医院药房

免疫治疗市场：依最终用户分类

• 市场概况
• 医院/诊所
• 门诊手术中心
• 其他的

免疫疗法市场：按地区

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 阿拉伯联合大公国国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市集活动
• 主要企业市场占有率（2023年）

主要企业简介

• Merck & Co., Inc.（United States）
• Johnson & Johnson Services, Inc.（United States）
• F. Hoffmann-La Roche Ltd.（Switzerland）
• AstraZeneca（United Kingdom）
• Pfizer Inc.（United States）
• Amgen Inc.（United States）
• Novartis AG（Switzerland）
• Eli Lilly and Company（United States）
• Sanofi（France）
• Bristol-Myers Squibb Company（United States）
• Gilead Sciences, Inc.（United States）
• Takeda Pharmaceutical Company Limited（Japan）
• Teva Pharmaceutical Industries Ltd.（Israel）
• AbbVie Inc.（United States）
• GSK PLC（United Kingdom）
• Immunocore Holdings Plc（United Kingdom）
• Astellas Pharma Inc.（Japan）
• Genmab A/S（Denmark）
• MacroGenics, Inc.（United States）
• Ferring BV（Switzerland）

Global Immunotherapy Drugs Market size was valued at around USD 247.44 billion in 2022 and is expected to rise from USD 285.30 billion in 2023 to reach a value of USD 772.87 billion by 2031, at a CAGR of 15.3% over the forecast period (2024-2031).

The global market for immunotherapy drugs is witnessing significant growth, primarily driven by the rising incidence of chronic diseases, particularly diabetes, which affected an estimated 537 million adults aged 20-79 in 2021 and is projected to escalate to 783 million by 2045, according to the International Diabetes Federation. Major market players are increasingly focusing on innovative product development and strategic partnerships to enhance research in immunotherapy. The COVID-19 pandemic has further accelerated this growth by increasing the demand for immunotherapy-related drugs, exemplified by findings published in January 2021 that highlighted the effectiveness of monoclonal antibodies in preventing hospitalizations for high-risk COVID-19 patients. The surge in regulatory approvals for immunotherapy products also supports market expansion. Key growth factors include the growing preference for targeted therapies over conventional treatments, the introduction of biosimilars, the rise in lifestyle-related disorders, and heightened consumer demand for monoclonal antibodies. Additionally, an upsurge in collaborations, the establishment of research laboratories, and significant R&D investments by biotechnology and pharmaceutical firms contribute to the market's momentum. Together, these dynamics are poised to create a robust landscape for immunotherapy drug development and commercialization in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Immunotherapy Drugs market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Immunotherapy Drugs Market Segmental Analysis

Global Immunotherapy Drugs Market is segmented by Type, Route of Administration, Application, Distribution Channel, End User and Region. Based on Type, the market is segmented into Antibody Drugs Inhibitor Drugs, Interferons and Interleukins, Cancer Vaccines, and Other Types. Based on Route of Administration, the market is segmented into Intravenous, Subcutaneous, and Other Routes of Administration. Based on Application, the market is segmented into Cancer, Autoimmune and Inflammatory Diseases, Hematology, Osteology, Neurology, and Other Applications. Based on Distribution Channel, the market is segmented into Retail Pharmacies, Online Pharmacies, and Hospital Pharmacies. Based on End User, the market is segmented into Hospitals, Long-Term Care Facilities, and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Immunotherapy Drugs Market

The global immunotherapy drugs market is significantly propelled by the rising prevalence of chronic diseases, notably cancer, autoimmune disorders, and infectious diseases. As lifestyles evolve and populations age, the demand for innovative and effective treatment options surges, creating a substantial market opportunity. Immunotherapy offers promising solutions, often leading to potential cures and improved patient outcomes, which further drives its adoption. Additionally, heightened awareness and advancements in diagnostic techniques contribute to early detection and treatment, thereby increasing the patient pool relying on immunotherapeutic agents. Collectively, these factors are expected to stimulate robust growth in the immunotherapy drugs market.

Restraints in the Global Immunotherapy Drugs Market

The Global Immunotherapy Drugs market faces significant restraints due to the challenging development process associated with these treatments. High costs linked to extensive clinical trials, research, and development pose a considerable barrier, limiting the entry of new players into the market. Additionally, the intrinsic complexity of immune system interactions necessitates personalized or group-oriented therapies, further complicating development and increasing expenses. These combined factors can deter investment and innovation, consequently hindering the emergence of new therapies and slowing overall market growth. The intricate regulatory landscape also contributes to these challenges, creating an environment that is less conducive to rapid advancement in immunotherapy.

Market Trends of the Global Immunotherapy Drugs Market

The Global Immunotherapy Drugs market is increasingly shifting towards personalized immunotherapy, fueled by advancements in precision medicine, genomics, and genetic engineering. This trend enables the development of treatments tailored to individual genetic profiles, disease history, and unique immune system characteristics, enhancing efficacy and minimizing side effects. With promising outcomes from clinical trials, pharmaceutical companies are investing significantly in personalized approaches, anticipating this shift will transform treatment paradigms for a range of conditions, including autoimmune diseases and cancers. As a result, the demand for bespoke immunotherapeutic solutions is set to accelerate, marking a pivotal evolution in the immunotherapy landscape.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factor
• Degree of Competition
• Top Investment Pockets
• Ecosystem of the Market
• Customer & Buying Criteria Analysis
• Value Chain Analysis
• Supply Chain Analysis
• Pricing Analysis
• Patent Analysis
• Technology Analysis
• Case Study Analysis
• Regulatory Landscape

Immunotherapy Drugs Market, By Type

• Market Overview
• Antibody Drugs
• Inhibitor Drugs
• Interferons & Interleukins
• Cancer Vaccines
• Other Immunotherapy Drugs

Immunotherapy Drugs Market, By Route of Administration

• Market Overview
• Intravenous Route of Administration
• Subcutaneous Route of Administration
• Other Routes of Administration

Immunotherapy Drugs Market, By Application

• Market Overview
• Cancer
• Autoimmune & Inflammatory Diseases
• Hematology
• Osteology
• Neurology
• Other Applications

Immunotherapy Drugs Market, By Distribution Channel

• Market Overview
• Retail Pharmacies
• Online Pharmacies
• Hospital Pharmacies

Immunotherapy Drugs Market, By End User

• Market Overview
• Hospitals & Clinics
• Ambulatory Surgical Centers
• Others

Immunotherapy Drugs Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Merck & Co., Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche Ltd. (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK PLC (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Immunocore Holdings Plc (United Kingdom)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Genmab A/S (Denmark)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MacroGenics, Inc. (United States)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Ferring BV (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments